Novo Nordisk Taps European Approvals and a Gulf Hub as US Price Pressure Persists

Novo Nordisk gains EU endorsements for oral and high-dose Wegovy, plans MASH data, and builds a UAE logistics hub to reduce reliance on US market amid pricing pressure.

The Danish drugmaker is signalling that its growth story no longer hinges solely on the American market. On Friday, the stock closed 1.25 percent higher at EUR 38.74, buoyed by a pair of European regulatory endorsements and a strategic logistics expansion in the United Arab Emirates. The moves come as Novo Nordisk navigates a fundamental tension: surging demand for its GLP-1 therapies is colliding with persistent pricing headwinds in the United States, where adjusted revenues fell 11 percent in the first quarter.

Two New Wegovy Formats Clear a Key Hurdle

The Committee for Medicinal Products for Human Use of the European Medicines Agency issued positive opinions on 22 May for two novel Wegovy formulations. The first is a once-daily oral semaglutide tablet at 25 mg — Novo Nordisk bills this as the first oral GLP-1 receptor agonist recommended by the CHMP for weight management in the EU. The OASIS-4 trial demonstrated a mean weight reduction of 16.6 percent with consistent use.

The second nod covers a 7.2 mg Wegovy pen, a higher-dose injectable for people living with obesity. In the STEP-UP study, that dose produced an average weight loss of 20.7 percent, and roughly one in three participants shed at least a quarter of their body weight. Novo Nordisk expects to launch the 7.2 mg pen in the EU during the third quarter of 2026; in the US, it already sells under the name Wegovy HD.

Although CHMP endorsements are a critical regulatory milestone, Brussels has the final say. A positive Commission decision is widely anticipated, and investors are watching to see whether a fuller European obesity portfolio can offset some of the pressure coming from across the Atlantic.

MASH Data Adds a Metabolic Dimension

Beyond the weight-loss pipeline, the company is broadening the therapeutic scope of semaglutide. At the EASL Congress in Barcelona from 27 to 30 May, Novo Nordisk plans to present liver safety analyses, subgroup evaluations, and real-world evidence on the drug in metabolic dysfunction-associated steatohepatitis. The strategic rationale is clear: more than 250 million people worldwide have MASH, over 40 percent of them also have type 2 diabetes, and more than eight in ten are living with obesity. Positioning semaglutide as a therapy for a wider metabolic syndrome — not just weight — could unlock a large new patient pool and strengthen the drug’s pricing argument.

A New Logistics Hub in the Emirates

On the operational side, Novo Nordisk is building a distribution centre in the United Arab Emirates. The facility will be one of three global hubs, designed to supply up to 70 countries across the Gulf, Africa, and Central Asia and support access for more than 2.6 million patients. The move ties together production sites in Europe, Asia, and the Americas with faster-growing markets where demand for diabetes, obesity, and other chronic disease therapies is rising sharply.

The timing is deliberate. In the first quarter, the company’s international sales rose 6 percent on a currency-adjusted basis, while US adjusted revenues fell 11 percent after lower realised prices ate into volume growth. Adjusted for the reversal of a 340B provision, the group’s total revenue declined 4 percent at constant currencies — even as obesity drug sales jumped 22 percent. The new hub does not immediately alter the profit-and-loss statement, but it shores up delivery capacity in precisely the regions that are becoming more important to the growth narrative.

Earnings, Outlook and Analyst Divergence

Novo Nordisk raised its full-year guidance after the Q1 report on 6 May, citing higher GLP-1 revenue expectations. Net sales reached roughly DKK 96.8 billion, with obesity revenue climbing 22 percent at constant exchange rates. Yet the company still forecasts a currency-adjusted decline in both adjusted revenue and adjusted operating profit of between 4 and 12 percent for 2026, excluding the 340B effect.

Analysts remain split. Based on 23 ratings, the consensus is neutral. Kepler Cheuvreux has a hold rating with a target of DKK 290, while Bernstein SocGen Group is more cautious with a sell and DKK 200. The range reflects the core challenge: strong volume momentum on one side, but margins squeezed by rebates and access restrictions, particularly in the US.

Technical Picture and Key Levels

At EUR 38.74, the stock sits roughly 11.5 percent above its 50-day moving average, signalling a short-term recovery. It has climbed about 27 percent from the 52-week low of EUR 30.48 struck in March, but remains nearly 45 percent below the year’s high of EUR 70.13. The relative strength index of 47 indicates neither overbought nor oversold territory.

On a weekly basis, the gain was modest at 0.47 percent, while the monthly return stands at 16.20 percent. Year to date, however, the share is still down 13.29 percent, and over 12 months it has lost 35.79 percent. Traders will watch whether the price can hold above EUR 39.37; a move toward EUR 42.19 would give the recovery more technical room to run. For now, the cocktail of European regulatory backing, MASH data, and a new Gulf distribution node offers a plausible narrative for investors looking beyond the US pricing drag.